Browse the evidence

Semaglutide treatment resulted in a 17% reduction in new-onset atrial fibrillation (AF) incidence compared to controls.

Semaglutide may be an effective treatment option for reducing the risk of new-onset AF in patients.

In trials without SGLT2 inhibitors, there was a significant reduction of 21% in new-onset AF.

Semaglutide may be more effective in reducing AF risk when not used with SGLT2 inhibitors.

In most existing algorithms for calculating prandial insulin doses in type 1 diabetes, only carbohydrates are counted.

Current algorithms may need to be revised to include more than just carbohydrate counting.

In type 2 diabetes, the meal content is often not taken into consideration when calculating prandial insulin doses.

Practitioners should consider meal content when determining insulin doses for type 2 diabetes.

Both groups displayed a decrease in baseline resistin values after 16 weeks of resistance training.

Resistance training may help lower resistin levels, which could be beneficial for metabolic health.

Semaglutide is associated with cardiovascular risk reduction.

Practitioners can consider semaglutide as a potential option for reducing cardiovascular risk in adults.

Treatment of metabolic changes at menopause requires a flexible long-term strategy.

Practitioners should develop adaptable treatment plans for managing menopause-related metabolic changes.

Preoperative fasting plasma C-peptide was predictive of increased chance of remission of type 2 diabetes after bariatric surgery (pooled difference in means = 0.93, 95% CI = 0.61 to 1.25, p < .001).

Practitioners may consider preoperative fasting C-peptide levels as a significant predictor for diabetes remission post-surgery.

SGLT-2 inhibitors and GLP-1 receptor agonists are effective in cardiovascular disease prevention among those with diabetes, heart failure, and chronic kidney disease.

Healthcare providers should consider these agents for patients with diabetes and related cardiovascular conditions.

GLP1-RA therapy appears safe and effective in patients with IBD.

GLP1-RA may be considered a treatment option for managing IBD.

GLP-1 receptor agonists have beneficial effects on atherosclerosis and cardiovascular disease.

Practitioners may consider GLP-1 receptor agonists as a treatment option for improving cardiovascular health in patients with obesity and type 2 diabetes.

Semaglutide reduced HbA1c by 0.46% of total hemoglobin in SGA-treated patients with schizophrenia, prediabetes, and obesity.

Semaglutide may be an effective treatment option for managing blood glucose levels in this patient population.

Semaglutide and tirzepatide show therapeutic potential as cardioprotective and nephroprotective agents.

Practitioners can consider semaglutide and tirzepatide for patients at risk of cardiovascular and renal diseases.

The GLP-1RA/GIPR antagonist MariTide achieved substantial reductions in weight and HbA1c.

MariTide may be an effective option for weight management and glycemic control in patients.

Current pharmacotherapy options for obesity include agents like liraglutide, semaglutide, and tirzepatide.

Practitioners should be aware of these specific pharmacotherapy options for treating obesity.

Novel therapies, including dual and triple incretin agonists, are under investigation for obesity treatment.

Practitioners should stay informed about emerging therapies that may enhance obesity treatment.

Male participants experienced greater effects than females (P < 0.001).

Practitioners should consider gender differences when designing resistance training programs.

GLP-1 receptor agonists and dual receptor agonists effectively counteract hyperglycemia and obesity.

These medications may be prioritized in treatment plans for T2D patients with obesity.

Unimolecular GLP-1/GCG dual agonist and GLP-1/GIP/GCG triple agonist may offer superior weight loss efficacy over GLP-1 agonist.

Practitioners should consider these new agonists for potentially better weight loss outcomes.

Recent patents emphasize the development of GLP-1 receptor agonists (GLP-1RAs) for oral delivery and improved weight reduction effects.

Practitioners should consider the potential of new GLP-1RAs that are orally administered and may enhance weight loss.

GLP-1 receptor agonists demonstrated a mean systolic BP reduction of -3.37 mmHg and a mean diastolic BP reduction of -1.05 mmHg compared with placebo.

GLP-1 receptor agonists can be considered for managing blood pressure in overweight or obese patients.

The BP reduction effect of GLP-1 RAs was consistent across subgroups for diabetic status, formulation, follow-up duration, and route of administration.

GLP-1 receptor agonists can be effectively used across different patient subgroups for BP management.

Tirzepatide is an efficacious and safe agent for the treatment of Type 2 Diabetes Mellitus (T2DM).

Practitioners can consider tirzepatide as a treatment option for managing T2DM.

Tirzepatide treatment significantly decreased serum glucose levels after fasting and improved glucose tolerance compared with semaglutide treatment.

Tirzepatide may offer better glycemic control than semaglutide in obese individuals.